GlassScriptPhysician profile
William Yang
NPI 1609005479
$66,178.34
in general payments reported to CMS, 2019-2025
37 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $7,505 · 2021: $5,773 · 2022: $7,870 · 2023: $14K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $11K · Honoraria: $2,000 · Travel and Lodging: $28.00 · Education: $18.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,407.20 |
| Food and Beverage | $10,788.58 |
| Honoraria | $2,000.00 |
| Travel and Lodging | $28.00 |
| Education | $18.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33,645.37 | 2021-2025 | |
| Vifor Pharma, INC. | $11,409.50 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $2,526.06 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,318.86 | 2019-2025 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $2,179.18 | 2019-2024 | Injectafer |
| Scpharmaceuticals INC. | $2,068.18 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,587.15 | 2019-2025 | Jynarque, Voyxact |
| Lilly USA, LLC | $1,211.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Csl Behring | $1,068.20 | 2024 | |
| Horizon Therapeutics Plc | $839.90 | 2019-2023 | Krystexxa |
| Novo Nordisk INC | $786.41 | 2019-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $776.67 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $708.57 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $665.07 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.26 | 2020-2025 | Jardiance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.